ISDA

Entry Detail

PDB ID:

7NQQ

Keywords:

SIGNALING PROTEIN

Title:

Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Escherichia coli BL21(DE3)

PDB Version:

Deposition Date:

2021-03-02

Release Date:

2021-10-06

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.94 Å

R-Value Free:

0.22

R-Value Work:

0.17

R-Value Observed:

0.17

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Mitogen-activated protein kinase 1
Chain IDs:A
Chain Length:368
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P28482 Pfam ID:PF00069 EC:2.7.11.24

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details	2D Image
CME	A	CYS	modified residue

Ligand Molecules

DMS

SO4

UMN

Primary Citation

Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2.

Heightman, T.D, Berdini, V, Bevan, L, Buck, I.M, Carr, M.G, Courtin, A, Coyle, J.E, Day, J.E.H, East, C, Fazal, L, Griffiths-Jones, C.M, Howard, S, Kucia-Tran, J, Martins, V, Muench, S, Munck, J.M, Norton, D, O'Reilly, M, Palmer, N, Pathuri, P, Peakman, T.M, Reader, M, Rees, D.C, Rich, S.J, Shah, A, Wallis, N.G, Walton, H, Wilsher, N.E, Woolford, A.J, Cooke, M, Cousin, D, Onions, S, Shannon, J, Watts, J, Murray, C.W.Show

J.Med.Chem. 64 12286 12303 (2021)

PMID: 34387469 DOI: 10.1021/acs.jmedchem.1c00905

Abstact

Aberrant activation of the mitogen-activated protein kinase pathway frequently drives tumor growth, and the ERK1/2 kinases are positioned at a key node in this pathway, making them important targets for therapeutic intervention. Recently, a number of ERK1/2 inhibitors have been advanced to investigational clinical trials in patients with activating mutations in B-Raf proto-oncogene or Ras. Here, we describe the discovery of the clinical candidate ASTX029 (15) through structure-guided optimization of our previously published isoindolinone lead (7). The medicinal chemistry campaign focused on addressing CYP3A4-mediated metabolism and maintaining favorable physicochemical properties. These efforts led to the identification of ASTX029, which showed the desired pharmacological profile combining ERK1/2 inhibition with suppression of phospho-ERK1/2 (pERK) levels, and in addition, it possesses suitable preclinical pharmacokinetic properties predictive of once daily dosing in humans. ASTX029 is currently in a phase I-II clinical trial in patients with advanced solid tumors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures